Sotera Health Company's Q1 Earnings Call: Our Top 5 Analyst Questions

Sotera Health’s first quarter results were well received by the market, as the company’s revenue and non-GAAP profit surpassed Wall Street’s expectations. Management credited this performance to stable demand across its sterilization and lab testing services, with Sterigenics benefiting from favorable pricing and steady volume trends. CEO Michael Petras highlighted the company’s ability to deliver “mid-single digit top-line growth and double-digit bottom line growth on a constant currency basis,” while also noting strong customer relationships and operational execution as contributing factors. Notably, the Nordion segment saw higher-than-anticipated revenue due to a shift in the timing of Cobalt-60 shipments, though this is expected to balance out over the coming quarters.

Is now the time to buy SHC? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions Sotera Health Company’s Q1 Earnings Call

• Patrick Donnelly (Citi) asked about the potential impact of tariffs and the company’s confidence in navigating them. CEO Michael Petras replied that current tariff policies are not expected to materially affect operations, with most revenue shielded by service-based business and trade agreements.
• Brett Fishbin (KeyBanc) inquired about drivers of Nelson Labs’ margin improvement and future trajectory. CFO Jonathan Lyons explained that stable labor, lab optimization, and regulatory-driven volume growth have supported margin gains, with continued progress expected.
• Matt Sykes (Goldman Sachs) questioned the legal risk strategy and cross-selling between Nelson Labs and Sterigenics. CEO Michael Petras emphasized confidence in defending legal claims and pointed to ongoing incentives and integration efforts to deepen cross-segment customer relationships.
• Luke Sergott (Barclays) sought clarification on margin sustainability, particularly after the Nordion shipment timing shift. CEO Michael Petras stated that margin improvement will be primarily sustained by Nelson Labs, with other segments remaining stable.
• Jason Bednar (Piper Sandler) asked about pricing stability in Sterigenics and potential customer pushback. CEO Michael Petras confirmed that price levels are defensible and consistent with long-term targets, with ongoing discussions reflecting the value delivered to customers.

Catalysts in Upcoming Quarters

In future quarters, the StockStory team will pay close attention to (1) the pace of volume recovery in Sterigenics and the sustainability of recent pricing gains, (2) whether Nelson Labs can maintain its margin expansion amid regulatory changes and advisory service headwinds, and (3) the normalization of Nordion’s revenue as shipment timing effects subside. Ongoing litigation outcomes and any regulatory developments related to ethylene oxide emissions will also be important markers to watch.

Sotera Health Company currently trades at $10.85, down from $11.49 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.

While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.